Pharmaceuticals

Prostate Cancer Therapeutics Market 2026 gaining traction with oncology advancements

March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Prostate Cancer Therapeutics Market In 2026 And What Value Is Projected For 2030?

The prostate cancer therapeutics market size has experienced robust growth in recent years. It is projected to expand from $12.88 billion in 2025 to $13.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. The historical increase can be attributed to factors such as rising prostate cancer incidence, an aging male population, advancements in oncology drugs, enhanced hospital-based cancer care, and increased cancer screening.

The prostate cancer therapeutics market size is projected to experience robust expansion in the coming years. It is expected to reach $19.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.4%. This anticipated growth during the forecast period can be attributed to the adoption of precision oncology, the development of biomarker-driven therapies, an increase in oral oncology drugs, an expanding immunotherapy pipeline, and rising healthcare expenditure. Significant trends for the forecast period include the increasing integration of targeted therapies, a rise in the use of PARP inhibitors, the broader application of immunotherapy in oncology, a shift towards oral cancer medications, and treatment selection based on precision medicine.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Major Drivers Are Influencing Demand In The Prostate Cancer Therapeutics Market?

The rising occurrence of prostate cancer is anticipated to propel the expansion of the prostate cancer therapeutics market moving forward. Prostate cancer is characterized by the development of malignant cells in the prostate gland tissues, typically affecting older men. The increasing rate of prostate cancer diagnoses is attributed to the aging population, as the risk of developing the disease substantially increases with age, and longer life expectancies mean more men live long enough to develop it. Prostate cancer therapeutics assist in managing the condition by targeting cancer cells, slowing progression, and improving patients’ quality of life through treatments such as surgery, radiation, hormone therapy, and newer options like immunotherapy. For instance, according to Prostate Cancer UK, a UK-based nonprofit cancer research and advocacy organization, in January 2025, the number of men diagnosed with prostate cancer rose from 50,751 cases in 2022 to 55,033 cases in 2023. Thus, the growing incidence of prostate cancer is a primary force driving the growth of the prostate cancer therapeutics market.

What Are The Key Segments Of The Prostate Cancer Therapeutics Market?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

What Key Trends Are Influencing The Development Of The Prostate Cancer Therapeutics Market?

Leading companies in the prostate cancer therapeutics market are concentrating on developing innovative treatments, such as a daily oral pill for advanced prostate cancer, to enhance patient compliance and improve overall treatment outcomes. This oral once-a-day pill for advanced prostate cancer refers to therapies administered daily to manage metastatic castration-resistant prostate cancer by inhibiting testosterone’s effects on cancer cells. For instance, in January 2024, Zydus Lifesciences, an India-based company, introduced Rexigo, India’s first daily oral pill containing relugolix for advanced prostate cancer patients. This convenient and affordable alternative to injectable hormone therapies rapidly suppresses testosterone, helping control cancer growth while offering an improved cardiovascular safety profile. As an oral therapy, it eliminates the need for injectable treatments that require administration by healthcare providers, thus offering greater patient convenience. This launch signifies a substantial advancement in prostate cancer management in India, providing patients and doctors with a new, convenient, safe, and cost-effective treatment option.

Who Are The Leading Companies Operating In The Prostate Cancer Therapeutics Market?

Major companies operating in the prostate cancer therapeutics market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Sanofi S.A., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Telix Pharmaceuticals, Bayer AG, Curium Pharma SAS, Dendreon Pharmaceuticals, Myovant Sciences GmbH, Clovis Oncology Inc., Ipsen S.A., Veru Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Dendreon Pharmaceuticals LLC, Pfizer Inc., Ferring B.V.

Read the full prostate cancer therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Prostate Cancer Therapeutics Market?

North America was the largest region in the prostate cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Prostate Cancer Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Therapeutics Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Urothelial Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795